Literature DB >> 30381674

Evaluation of miR-122 to Predict High Dose Acetaminophen-Induced Liver Injury in Mice: The Combination Uses of 5-Fluorouracil.

Chie Munakata1,2, Yuki Fuchigami1, Shu Hiroishi1, Ayana Haraguchi1, Masayori Hagimori1, Hatsune Enomoto3, Hidehisa Tachiki3, Yukinobu Kodama2, Hitoshi Sasaki2, Shigeru Kawakami1.   

Abstract

Administration of high doses of acetaminophen (APAP) is known to cause drug-induced liver injury (DILI) in humans. Therefore, the detection or prediction of these side-effects at an early stage using appropriate biomarkers is the need of the hour. Micro RNA (miR)-122 is expected to be a novel biomarker for liver injury. However, more evidence is required in various alternate situations such as its use in combination as APAP is often used along with anticancer drugs. In the present study, we aimed to evaluate the functions of miR-122 as a biomarker for liver injury in comparison with alanine aminotransferase (ALT) in a mice model with the APAP-induced liver injury (AILI). Consequently, there was a dose-dependent increase in miR-122 after administration of APAP intraperitoneally. Similar observations were made for ALT activity. Additionally, the expression of miR-122 increased in a more rapid manner compared to ALT activity. However, there was a variation in the miR-122 expression. Further, we investigated the drug-drug interaction between APAP and 5-fluorouracil using miR-122 and ALT in mice. As a result, the degree of AILI was not changed by the use of 5-fluorouracil in combination with APAP in mice.

Entities:  

Keywords:  acetaminophen; biomarker; liver injury; micro RNA-122

Mesh:

Substances:

Year:  2018        PMID: 30381674     DOI: 10.1248/bpb.b18-00504

Source DB:  PubMed          Journal:  Biol Pharm Bull        ISSN: 0918-6158            Impact factor:   2.233


  2 in total

1.  Circulating microRNA Profiles in Acetaminophen Toxicity.

Authors:  Stephanie Carreiro; James Marvel-Coen; Rosalind Lee; Brittany Chapman; Victor Ambros
Journal:  J Med Toxicol       Date:  2019-12-02

2.  The Variant at TGFBRAP1 but Not TGFBR2 Is Associated with Antituberculosis Drug-Induced Liver Injury.

Authors:  Jingwei Zhang; Zhenzhen Zhao; Hao Bai; Lin Jiao; Qian Wu; Tao Wu; Tangyuheng Liu; Xuejiao Hu; Jiajia Song; Mengyuan Lyv; Binwu Ying
Journal:  Evid Based Complement Alternat Med       Date:  2019-08-22       Impact factor: 2.629

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.